Evaluation of the 25 Centimeter (cm) GORE® VIABAHN® Endoprosthesis

Inclusion Criteria: * Lifestyle-limiting claudication or rest pain (meeting angiographic entry criteria) affecting a lower extremity (Rutherford Categories 2-4). * A written informed consent form, which has been reviewed and approved by the Ethics Committee, has been read, understood and signed by the subject (or their legally authorized representative). * At least 21 years of age. * Noninvasive lower extremity arterial studies (ankle-brachial index, ABI) prior to (within 45 days) or at the time of the study procedure demonstrating a resting ankle-brachial index (ABI) ≤ 0.9 in the study limb. If ABI \> 0.9, patient is eligible for study if toe-brachial index (TBI) is ≤ 0.5. * A staged ipsilateral vascular procedure was not completed less than 30-days prior to the study procedure. Resting ABIs were completed prior to the study procedure a minimum of 30-days after the staged vascular procedure. * Vascular treatment on the non-study leg for bilateral claudication was not performed less than 30-days prior to study procedure. Resting ABIs on the study limb were completed prior to the study procedure a minimum of 30-days after treatment on the non-study leg. * Male, infertile female, or female of child bearing potential practicing an acceptable method of birth control with a negative pregnancy test within 7-days prior to study procedure. * Projected life expectancy of greater than three years. * The ability to comply with protocol follow-up requirements and required testing. * Angiographic and Lesion Requirements (assessed intraoperatively): * Lesion length of 20-35 cm located in the region beginning 1 cm below origin of the profunda femoris artery and ending 1 cm above the origin of the intercondylar fossa. * De novo, post-percutaneous transluminal angioplasty (PTA), or post-atherectomy stenosis (\> 50% at some point within the lesion by visual estimate) or occlusion of native SFA. * Origin and proximal 1 cm of SFA are patent. * Popliteal artery is patent from 1 cm above the origin of the intercondylar fossa distal to the radiographic knee joint. * Reference vessel diameter of 4.0 - 7.5 mm in proximal and distal treatment segments within the SFA. * Angiographic evidence of at least one patent tibial artery to the ankle that does not require intervention. * Guidewire has successfully traversed lesion and is within the true lumen of the distal vessel. Exclusion Criteria: * Untreated flow-limiting aortoiliac occlusive disease. * Any previous open surgical procedure in the target vessel or previous stent placement in the target vessel. * Prior angioplasty on the target lesion performed less than 30 days prior to the study procedure (unless performed at time of the study procedure). * Prior atherectomy on the target lesion performed less than 6 months prior to the study procedure (unless performed at time of the study procedure). * Any previous treatment of the target vessel with a drug-eluting balloon. * Femoral artery or popliteal artery aneurysm. * Non-atherosclerotic disease resulting in occlusion (e.g. embolism, Buerger's disease, vasculitis). * Tibial artery disease requiring treatment. * Prior ipsilateral femoral artery bypass. * Severe medical comorbidities (untreated coronary artery disease, congestive heart failure, severe chronic obstructive pulmonary disease, metastatic malignancy, dementia, etc.) or other medical condition that would preclude post-procedural ambulation. * Popliteal artery vascular access at any time during procedure. * Antegrade and retrograde vascular access on the same common femoral artery at the time of the SFA intervention. * Major distal amputation (above the transmetatarsal) in the study or non-study limb. * Septicemia. * Any previously known coagulation disorder, including hypercoagulability. * Morbid obesity or operative scarring that precludes percutaneous approach (physician's discretion). * Contraindication to anticoagulation or antiplatelet therapy. * Known allergies to stent/stent-graft components, including heparin sensitivity, allergy, or previous incidence of heparin-induced thrombocytopenia (HIT) type II. * History of prior life-threatening reaction to contrast agent. * Currently participating in another clinical research trial, unless approved by W. L. Gore \& Associates in advance of study enrollment. * Subject has one limb currently enrolled in the study. * Current peritoneal or hemodialysis.